SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-23-017657
Filing Date
2023-11-06
Accepted
2023-11-06 07:22:32
Documents
15
Period of Report
2023-11-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K plx-20231106x8k.htm   iXBRL 8-K 40433
2 EX-99.1 plx-20231106xex99d1.htm EX-99.1 215804
3 GRAPHIC plx-20231106xex99d1001.jpg GRAPHIC 5450
  Complete submission text file 0001558370-23-017657.txt   492548

Data Files

Seq Description Document Type Size
4 EX-101.SCH plx-20231106.xsd EX-101.SCH 3465
5 EX-101.LAB plx-20231106_lab.xml EX-101.LAB 1354
6 EX-101.PRE plx-20231106_pre.xml EX-101.PRE 11110
9 EXTRACTED XBRL INSTANCE DOCUMENT plx-20231106x8k_htm.xml XML 4864
Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

IRS No.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33357 | Film No.: 231378109
SIC: 2836 Biological Products, (No Diagnostic Substances)